David Preiss is Professor of Metabolic Medicine and Clinical Trials at the University of Oxford, and has been based there since 2015. He previously worked at the University of Glasgow where he completed his PhD. His major interests are the prevention of cardiovascular disease (CVD) and microvascular complications of diabetes, with particular focus on lipid modification and glucose lowering. He is Chief Investigator for the ongoing ASCEND PLUS trial (oral semaglutide for the prevention of complications in T2DM) and Co-PI for the ORION-4 trial (PCSK9 synthesis inhibition in a secondary prevention population). He led the recent LENS trial, which showed the benefit of fenofibrate for diabetic retinopathy progression, and was Co-PI for the EMPA-KIDNEY trial which demonstrated the benefit of SGLT2 inhibition in patients with chronic kidney disease. He is a member of the Cholesterol Treatment Trialists' Collaboration Secretariat which performs IPD meta-analyses of major statin trials.